PolyNovo Limited responded to an ASX price query on 14 May 2026 after its share price jumped from a low of $1.01 at close on 13 May to a high of $1.19 the following day, accompanied by a significant spike in trading volume. The Australian Securities Exchange sought clarification on whether the company was aware of any undisclosed material information that could explain the sharp movement in its securities.
In its response, PNV confirmed that it is not aware of any information concerning the company that has not been announced to the market which, if known by some investors, could explain the recent trading activity. The company further stated it is not aware of any other explanation for the movement and confirmed compliance with ASX Listing Rule 3.1, which requires continuous disclosure of material information. The response was authorised by the company’s board in accordance with its published continuous disclosure policy.
The ASX’s decision to issue a price query reflects established protocols designed to maintain market integrity when share price movements are significant and accompanied by unusual trading volume. The exchange investigates whether a company has withheld information it is required to disclose. The fact that PNV could offer no explanation suggests either that sector trends, investor sentiment, or other market-wide factors drove the appreciation, or that trading resulted from routine portfolio rebalancing and accumulation by larger investors without a specific company catalyst.
For investors holding or considering PNV, the response provides assurance that there are no material developments lurking beneath the surface. The absence of undisclosed information means the 18 percent price movement reflects market sentiment about existing public information rather than new news breaking unevenly across the market. This reduces concerns about information asymmetry, though it leaves the fundamental driver of the rally unexplained.
Investors monitoring PNV should consider whether the movement represents a rerating of the business based on existing data, growing institutional interest in the stock, or technical momentum. The company’s next quarterly or annual results will provide the next scheduled opportunity to assess the underlying business trajectory, though investors should monitor ASX announcements for any material updates in the interim. This response is flagged as price sensitive and has been identified as a material announcement by the ASX.
View the full ASX announcement (PDF)
About PolyNovo Limited (ASX: PNV)
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices for surgical and trauma applications, with a primary focus on dermal regeneration matrices and reconstructive surgery products. The company develops innovative biocompatible polymer solutions used in burn treatment, wound management, and emerging applications including hernia repair and pancreatic implants. It operates across multiple international markets including Australia, New Zealand, the United States, and Europe.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
